BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chan P, Li H, Zhu L, Bifano M, Eley T, Osawa M, Ueno T, Hughes E, Bertz R, Garimella T, AbuTarif M. Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection. Clin Pharmacokinet 2017;56:1173-83. [PMID: 28066880 DOI: 10.1007/s40262-016-0504-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Gandhi Y, Eley T, Fura A, Li W, Bertz RJ, Garimella T. Daclatasvir: A Review of Preclinical and Clinical Pharmacokinetics. Clin Pharmacokinet. 2018;57:911-928. [PMID: 29353349 DOI: 10.1007/s40262-017-0624-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
2 Osawa M, Ueno T, Shiozaki T, Ishikawa H, Li H, Garimella T. Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects. Clin Pharmacol Drug Dev 2019;8:802-17. [PMID: 30629858 DOI: 10.1002/cpdd.649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Wang HC, Ren YP, Qiu Y, Zheng J, Li GL, Hu CP, Zhou TY, Lu W, Li L. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C. Acta Pharmacol Sin 2018;39:140-53. [PMID: 28880015 DOI: 10.1038/aps.2017.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
4 Osawa M, Ueno T, Ishikawa H, Imai Y, Garimella T. Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection. J Clin Pharmacol 2018;58:1468-78. [PMID: 30063254 DOI: 10.1002/jcph.1274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Mastrorosa I, Tempestilli M, Notari S, Lorenzini P, Fabbri G, Grilli E, Bellagamba R, Vergori A, Cicalini S, Ammassari A, Agrati C, Antinori A. Association of Sofosbuvir and Daclatasvir Plasma Trough Concentrations with Patient-, Treatment-, and Disease-Related Factors Among HIV/HCV-Coinfected Persons. Eur J Drug Metab Pharmacokinet 2021. [PMID: 34623616 DOI: 10.1007/s13318-021-00725-w] [Reference Citation Analysis]
6 Guan XD, Tang XG, Zhang YJ, Xie HM, Luo L, Wu D, Chen R, Hu P. Population Pharmacokinetic Analysis of Yimitasvir in Chinese Healthy Volunteers and Patients With Chronic Hepatitis C Virus Infection. Front Pharmacol 2020;11:617122. [PMID: 33584296 DOI: 10.3389/fphar.2020.617122] [Reference Citation Analysis]
7 Yu G, Zheng Y, Yu Y, Li GF, Derendorf H. Gastric-acid-mediated drug-drug interactions with direct-acting antiviral medications for hepatitis C virus infection: clinical relevance and mitigation strategies. Drug Discov Today 2019;24:845-57. [PMID: 30648608 DOI: 10.1016/j.drudis.2019.01.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Chen L, Ye X, Hu K, Zhai Y, Li W, Wang X, Yang J. Population pharmacokinetic modeling and simulation of HPPH in Chinese patients with esophageal carcinoma. Xenobiotica 2020;50:170-7. [PMID: 30901299 DOI: 10.1080/00498254.2019.1597315] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]